Home/Filings/4/0001209191-22-048508
4//SEC Filing

ROBIN SHERRINGTON 4

Accession 0001209191-22-048508

CIK 0001582313other

Filed

Sep 1, 8:00 PM ET

Accepted

Sep 2, 4:27 PM ET

Size

24.0 KB

Accession

0001209191-22-048508

Insider Transaction Report

Form 4
Period: 2022-08-31
Transactions
  • Tax Payment

    Common Shares

    2022-09-01$38.81/sh6,121$237,55660,675 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-0150,0000 total
    Exercise: $4.75Exp: 2028-03-11Common Shares (50,000 underlying)
  • Exercise/Conversion

    Common Shares

    2022-08-31$2.67/sh+17,488$46,69334,720 total
  • Exercise/Conversion

    Common Shares

    2022-08-31$4.75/sh+5,000$23,75039,720 total
  • Tax Payment

    Common Shares

    2022-08-31$37.86/sh1,572$59,51638,148 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2022-08-3117,4880 total
    Exercise: $2.67Exp: 2022-12-31Common Shares (17,488 underlying)
  • Sale

    Common Shares

    2022-08-31$38.57/sh21,352$823,54716,796 total
  • Exercise/Conversion

    Common Shares

    2022-09-01$4.75/sh+50,000$237,50066,796 total
  • Sale

    Common Shares

    2022-09-01$38.03/sh35,103$1,334,96725,572 total
  • Sale

    Common Shares

    2022-09-01$38.80/sh8,776$340,50916,796 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2022-08-315,0000 total
    Exercise: $4.75Exp: 2028-03-11Common Shares (5,000 underlying)
Footnotes (6)
  • [F1]Represents the closing price of the Company's common shares on August 30, 2022 for purposes of net settlement calculations.
  • [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F3]Represents the closing price of the Company's common shares on August 31, 2022 for purposes of net settlement calculations.
  • [F4]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.44 to $38.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F5]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.73 to $38.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F6]The shares subject to the option are fully vested and exercisable.

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1
  • filerCIK 0001619962

Filing Metadata

Form type
4
Filed
Sep 1, 8:00 PM ET
Accepted
Sep 2, 4:27 PM ET
Size
24.0 KB